KHPG(SZ:002773) Ge Long Hui·2025-09-29 03:57Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Ipatasertib tablets, indicating a significant regulatory approval for a new treatment for diabetic neuropathy [1][2]. Group 1: Drug Information - Drug Name: Ipatasertib Tablets [1] - Dosage Form: Tablet [1] - Specification: 50mg [1] - Indication: Diabetic neuropathy [1] Group 2: Regulatory Approval - Registration Classification: Chemical Drug Class 3 [2] - Approval Number: National Drug Approval Code H20255572 [2] - Approval Conclusion: The drug meets the requirements for registration as per the Drug Administration Law of the People's Republic of China [2]. Group 3: Mechanism and Clinical Research - Ipatasertib is a reversible non-competitive inhibitor of aldose reductase, selectively inhibiting the enzyme [2]. - Clinical studies have shown that Ipatasertib can inhibit the accumulation of sorbitol in red blood cells of patients with diabetic peripheral neuropathy, improving subjective symptoms and neurological dysfunction compared to the control group [2].